7,917
Views
7
CrossRef citations to date
0
Altmetric
Report

Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice

, , , , , , , & ORCID Icon show all
Article: 2107971 | Received 18 May 2022, Accepted 27 Jul 2022, Published online: 03 Aug 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Izabela Lepiarz-Raba, Taufik Hidayat, Anthony J. Hannan & Ali Jawaid. (2024) Potential Alzheimer’s disease drug targets identified through microglial biology research. Expert Opinion on Drug Discovery 19:5, pages 587-602.
Read now

Articles from other publishers (6)

Sujun Jiang, Guoen Cai, Zhimin Yang, Haoyuan Shi, Huajie Zeng, Qinyong Ye, Zhiyuan Hu & Zihua Wang. (2024) Biomimetic Nanovesicles as a Dual Gene Delivery System for the Synergistic Gene Therapy of Alzheimer’s Disease. ACS Nano 18:18, pages 11753-11768.
Crossref
Joanna Mackiewicz, Malwina Lisek & Tomasz Boczek. (2023) Targeting CaN/NFAT in Alzheimer’s brain degeneration. Frontiers in Immunology 14.
Crossref
Kai Schlepckow, Estrella Morenas-Rodríguez, Soyon Hong & Christian Haass. (2023) Stimulation of TREM2 with agonistic antibodies—an emerging therapeutic option for Alzheimer's disease. The Lancet Neurology 22:11, pages 1048-1060.
Crossref
Marina Passero, Tianhua Zhai & Zuyi Huang. (2023) Investigation of Potential Drug Targets for Cholesterol Regulation to Treat Alzheimer’s Disease. International Journal of Environmental Research and Public Health 20:13, pages 6217.
Crossref
Gunel Ayyubova. (2023) TREM2 signalling as a multifaceted player in brain homoeostasis and a potential target for Alzheimer's disease treatment. European Journal of Neuroscience 57:4, pages 718-733.
Crossref
Wandong Zhang. 2024. Drug Delivery and Targeting. Drug Delivery and Targeting 213 230 .